# "Unifuzol®" in Patients With Peripheral Arterial Disease

> **NCT03861416** · PHASE2 · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 360 (actual)

## Conditions studied

- Peripheral Arterial Disease

## Interventions

- **DRUG:** L-arginine 1.4% 500 ml
- **DRUG:** L-arginine 1.4% 250 ml + placebo 250 ml
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT03861416
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2019-09-13
- **Final completion:** 2019-10-26
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2020-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861416, ""Unifuzol®" in Patients With Peripheral Arterial Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03861416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*